Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...

Boehringer Ingelheim’s weight-loss drug candidate ... stage MASH trial and has the potential to become a best-in-class treatment for the progressive disease, which affects more than 115 million ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Ono Pharma and Boehringer Ingelheim both added to their cancer ... which have transformed the treatment of various cancer types in recent years and have become sought-after assets in pharma.

Certain hormonal contraceptives are associated with a higher stroke and heart attack risk, finds a large study from Denmark in The BMJ today that draws on prescription records to give more precise ...

Terns Pharmaceuticals' TERN-701 and TERN-601 face challenges in CML and obesity. Find out why TERN stock is not a strong buy amid tough competition.

Grossman School of Medicine, New York ... Has consulted for Sangamo Therapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; sanofi-aventis; Novartis Pharmaceuticals Corporation (all ...

The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...

The global Diabetes Drugs Market size was valued at USD 84.65 billion in 2024 and is expected to be worth around USD 177.74 ...